Chronic Total Occlusion: A case for coronary artery bypass grafting

Size: px
Start display at page:

Download "Chronic Total Occlusion: A case for coronary artery bypass grafting"

Transcription

1 Chronic Total Occlusion: A case for coronary artery bypass grafting Prof. Alfredo R Galassi MD, FESC, FACC, FSCAI Director of Cardiac Catheterization and Interventional Cardiology Unit Department of Medical Sciences and Pediatrics Division of Cardiology, Cannizzaro Hospital, University of Catania, Italy

2 Disclosure Statement of Financial Interest I, Alfredo Galassi DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation

3

4 CTOs are common and influence management Analysis of consecutive patients undergoing angiography ( ), CTO was found in 52% patients with significant (> 70% DS) coronary disease Christofferson et al, Am J Cardiol 2005

5 12 CENTERS The IRCTO Registry patients enrolled with 1968 CTO lesions CTO prevalence 12.3% 44% 46% Optimal medical therapy 826 pts PCI 776 pts 10% CABG 175 pts Tomasello et al, GIC 2012

6 CTO PCI Success Rate Over Years Toyohashi Heart Center % ,9 71, , ,2 86,3 92,4 92,2 91,6 91,5 92,

7 Course Directors Nicolaus Reifart Main Taunus Kliniken Bad Soden, Germany Gerald S. Werner Medizinische Klinik Klinikum Darmstadt Darmstadt, Germany Co-Directors Alfredo R. Galassi Ferrarotto Hospital University of Catania Catania, Italy George Sianos AHEPA University Hospital Thessaloniki, Greece Hans Bonnier University Hospital Brussels Brussels, Belgium

8 Success of CTO revascularization (%) 06/07: all members - since 2008 Online Registry Galassi et al, EuroIntervention 2011; 7: 472-9

9 Procedural and Fluoroscopy Time and Contrast Load (min) Procedure time (mean +SD) (min) Fluoroscopy time (mean +SD) ,3 1 hour and 40 mins 87,4 98, ,5 Overall LMT LAD LCX RCA Galassi et al, EuroIntervention ,9 219, ,2 45,3 36,3 (ml) Contrast load (mean +SD) 300 cc 45 mins 52,5 36,7 44,3 Overall LMT LAD LCX RCA 285,7 293,5 0 Overall LMT LAD LCX RCA

10 The EURO CTO Registry: A web-based registry ( OTHER COMPLICATIONS In Hospital Complications MACE (Major Adverse Cardiac Events) MI (Q-Wave, Non Q-Wavw) n (%) 21 (1.4) Cardiac Death n (%) 6 (0.4) Emergency CABG n (%) 3 (0.2) Emergency re-pci n (%) 2 (0.1) Stent Trombosis n (%) - Stroke n (%) 1 (0,1) Contrast Induced nephropathy) n (%) 17 (1.2) Coronary Perforation n (%) 37 (2.5) Cardiac Tamponade n (%) 11 (0.8) Vascular Complications n (%) 12 (0.8) BLEEDING Major Bleeding n (%) - Hb Reduction of > 5g/dL n (%) 1 (0.1) All other Bleeding not included as major n (%) 4 (0.3) Galassi et al, EuroIntervention 2011; 7: 472-9

11 J-CTO Multicenter Registry in Japan (498 pts, 528 lesions) Morino et al, JACC Intv 2010

12 Shah PB, Circulation 2011; 123:

13 Seven randomized studies sorted by FU lenght

14 RCA CTO Single-vessel Patient Clinical Presentation Exertional angina and dyspnea (CCSC III) Risk Factors Hypertension Dyslipidemia Non-invasive Testing Patient: V-S, male, 6 yrs 2D Echo: hypokinesia of inferior wall, EF 48%

15 RCA CTO Single-vessel Patient CTO PCI with DES

16 LAD CTO in a CABG Patient Risk Factors Patient: A-S, male, 60 yrs Past/Clinical hystory Hypertension Dyslipidemia Ex-smoker NID Diabetes Family history of CAD CABG: RIMA on lad, LIMA on OM, SVG on PDA 1999 Clinical Presentation September 2011: NSTEMI with ECG changes in lateral leads

17 LAD CTO in a CABG Patient

18 LAD CTO in a CABG Patient PCI with DES on native OM

19 LAD CTO in a CABG Patient Clinical Presentation March 2012:exertional angina and dyspnea (CCSC III) Non-invasive Testing Nuclear stress test: antero-septal reversible perfusion defect 2D Echo: hypokinesia of anterior wall, EF 55% Patient: A-S, male, 60 yrs CTO PCI with DES

20 LAD CTO in Single Vessel Disease Patient: V-M, female, 28 yrs Clinical Presentation Exertional angina and dyspnea (CCSC II) Risk Factors Family history of CAD Past/Clinical hystory Hodgkin Lymphoma treated with chemio- and radiotherapy 2005 Exertional angina since 2010 Non-invasive Testing Coronary MSCT: proximal LAD CTO 2D Echo: normokinesia of all segments, EF 60%

21 LAD CTO in Single Vessel Disease CTO PCI with DES

22 The EURO CTO Registry: A web-based registry ( CTO Vessel Distribution % % LAD LCX RCA LMT Procedural complication Angiographic Outcome % Galassi et al, EuroIntervention 2011; 7: 472-9

23 Evolution of DES as a standard in CTO Revascularization

24 Evolution of DES as a standard in CTO Revascularization

25 Evolution of DES as a standard in CTO Revascularization

26 Evolution of DES as a standard in CTO Revascularization

27 Evolution of DES as a standard in CTO Revascularization

28 Evolution of DES as a standard in CTO Revascularization

29 Evolution of DES as a standard in CTO Revascularization

30 Shah PB, Circulation 2011; 123:

31 Coronary angiographic findings in NSTEMI-ACS and STEMI patients Non-obstructive 40-50% Left main 4-10% Anderson et al, JACC 2007, Goldstein et al NEJM 2000

32 LAD CTO in a STEMI Multi-vessel Patient Clinical Presentation August 2011: lateral STEMI Risk Factors Hypertension Dyslipidemia Ex-smoker Patient: N-D, male, 63 yrs

33 LAD CTO in a STEMI Multi-vessel Patient Primary PCI with DES

34 LAD CTO in a STEMI Multi-vessel Patient Clinical Presentation March 2012: Exertional angina and dyspnea (CCSC III) Non-invasive Testing 2D Echo: hypokinesia of antero-septal wall, EF 44% Dobutamine Echo-Stress: bi-phasic response to dobutamine infusion Patient: N-D, male, 63 yrs CTO PCI with DES

35 TOAST study Olivari et al, JACC 2003

36 RCA CTO in a NSTEMI Multivessel Patient Risk Factors Hypertension Dyslipidemia Smoker Clinical Presentation August 2012 : NSTEMI Patient: V-P, female, 56 yrs

37 RCA CTO in a STEMI Patient

38 Rationale for CTO PCI in case of MVD A staged approach is reasonable in order to avoid excessively long procedures Which artery to tackle first, the CTO or the non CTO should be based on the importance of the vessel which is the first artery to be treated Inverted collateral flow through the recanalised CTO may protect the myocardium at risk during high risk complex lesions in the collateral donor vessel Sianos et al, EuroIntervention 2012

39 Course Directors Nicolaus Reifart Main Taunus Kliniken Bad Soden, Germany Gerald S. Werner Medizinische Klinik Klinikum Darmstadt Darmstadt, Germany Co-Directors Alfredo R. Galassi Ferrarotto Hospital University of Catania Catania, Italy George Sianos AHEPA University Hospital Thessaloniki, Greece Hans Bonnier University Hospital Brussels Brussels, Belgium

40 Success rate and case load <40 / year / year / year >100 / year Galassi et al, EuroIntervention 2011;7:472-9

41 Consensus on Training and Centre/Operator Competency 1. All the Interventional Trainees should have the theoretical knowledge for appropriate patient and lesions selection and the practical experience to avoid the most common mistakes in CTO recanalization 2. Sufficient training to work as independent primary operator for most angioplasty procedures does not automatically translate into an ability to approach any CTOs 3. The minimal number of 50 CTOs per year to maintain competency traslates ì into a model where only a limited number of operators and centres should perform CTO treatment safely based on workload, auditel success and complication rates Sianos et al, EuroIntervention 2012

42 Conclusions 1 Recent evidence from the japanese and european registries showed an high CTO s PCI procedural success (85-95%) without rise in complications rates PCI for isolated RCA and LCX, small vessel disease, previously by-pass CTO s is indicated when ischemic symptoms are associated with myocardial ischemia and viability CTO s PCI of LAD, might be choosen as appropriate strategy when clinical indicated in case of single vessel disease

43 Conclusions 2 MVD patients and CTO should deserve PCI considering recent high PCI success in experienced hands with low complication rates and restenosis by use of DES Moreover, CTO are found frequently during primary PCI procedures, making reasonable to stage CTO PCI after revascularization of the culprit vessel CABG might be choosen considering patient risk profile and life expectancy (patient selection is crucial)

44 The Boomerang effect The favourable result of a CTO recanalization, by expert and dedicated operators should not detemin an excessive enthusiasm of PCI utilization beyond the real and actual needs, which in turn might cause an underestimation of the procedure efficacy

Trattamento delle CTO Indicazioni e risultati

Trattamento delle CTO Indicazioni e risultati Trattamento delle CTO Indicazioni e risultati Prof. Alfredo R. Galassi MD, FESC, FACC, FSCAI Department of Medical Sciences and Pediatrics, University of Catania, Italy and University Heart Center, University

More information

Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /

Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / / Patient Patient code Birth date: / / Sex: Male Height (cm): Female Weight (kg): Risk Factors: Family history of coronary disease: Hypertension Dyslipidemia Peripheral disease Diabetes Comorbidities: No

More information

Clinical Considerations for CTO

Clinical Considerations for CTO 38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research

More information

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

Chronic Total Occlusions. Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute

Chronic Total Occlusions. Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute Chronic Total Occlusions Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute Financial Disclosures /see -tee-oh / abbr. Med. Chronic Total Occlusion,

More information

J. Schwitter, MD, FESC Section of Cardiology

J. Schwitter, MD, FESC Section of Cardiology J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the

More information

Clinical Considerations for CTO Revascularization

Clinical Considerations for CTO Revascularization Clinical Considerations for CTO Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD, FACC, FSCAI Chief Medical Officer Cordis Cardiology Johnson & Johnson

More information

Lessons learned From The National PCI Registry

Lessons learned From The National PCI Registry Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients

More information

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang

More information

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao) The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang

More information

CASE from South Korea

CASE from South Korea CASE from South Korea Bon-Kwon Koo, MD, PhD, Seoul, Korea Outpatient clinic of a non-interventional cardiologist F/56 Chief complaint: Angina with recent aggravation, CCS II~III Brief history: # Stroke

More information

Complication management and long-term outcome after percutaneous coronary intervention

Complication management and long-term outcome after percutaneous coronary intervention Complication management and long-term outcome after percutaneous coronary intervention ESC meeting 2012, Munich, Germany Session: Chronic total occlusion: a challenge for percutaneous coronary intervention

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

CTO Re vascularization in 2013

CTO Re vascularization in 2013 CTO Re vascularization in 2013 Is it safe to use/stent the sub intimal space? Dimitri Karmpaliotis, MD, FACC, FSCAI Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia Dimitri.karmpaliotis@piedmont.org

More information

Coronary interventions

Coronary interventions Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF

More information

Chronic Total Occlusion: a case for coronary artery bypass grafting

Chronic Total Occlusion: a case for coronary artery bypass grafting Chronic Total Occlusion: a case for coronary artery bypass grafting Rune Haaverstad Professor & Chief Dept. of Cardiothoracic Surgery Haukeland University Hospital Bergen, Norway Disclosure Research cooperation

More information

ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική

ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική X. ΓΡΑΪΔΗΣ Επεμβατικός καρδιολόγος, FSCAI Kλινική Euromedica-Κυανούς Σταυρός, Θεσσαλονίκη The Fear factor The two words LEFT MAIN

More information

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures

More information

Stable Angina: Indication for revascularization and best medical therapy

Stable Angina: Indication for revascularization and best medical therapy Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang

More information

Clinical Summary. Live Cases I - IX

Clinical Summary. Live Cases I - IX Clinical Summary Live Cases I - IX Case #1 2017/09/16 Age: 66 Target Vessel: RCA proximal Relevant Diagnosis: Single vessel CAD with normal LVEF Coronary Risk Factors: Hypertension, smoke (90py) ECG abnormality:

More information

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016 Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization

More information

Debate Should we use FFR? I will say NO.

Debate Should we use FFR? I will say NO. Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea

More information

Benefit of Performing PCI Based on FFR

Benefit of Performing PCI Based on FFR Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided

More information

Cindy L. Grines MD FACC FSCAI

Cindy L. Grines MD FACC FSCAI Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in

More information

Masashi Kimura, MD Etsuo Tsuchikane, MD Osamu Katoh, MD Toyohashi Heart Center, Japan

Masashi Kimura, MD Etsuo Tsuchikane, MD Osamu Katoh, MD Toyohashi Heart Center, Japan Masashi Kimura, MD Etsuo Tsuchikane, MD Osamu Katoh, MD, Japan Retrograde Approach for Coronary CTO Collateral channels A. bypass graft B. epicardial collateral C. septal perforator Retrograde wiring techniques

More information

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical

More information

The Role of the Retrograde Approach in Percutaneous Coronary Interventions for Chronic Total Occlusions : Insights from the Japanese Retrograde

The Role of the Retrograde Approach in Percutaneous Coronary Interventions for Chronic Total Occlusions : Insights from the Japanese Retrograde Interventional Cardiology The Role of the Retrograde Approach in Percutaneous Coronary Interventions for Chronic Total Occlusions : Insights from the Japanese Retrograde Summit Registry Background: Percutaneous

More information

Clinical Summary. Live Cases I - IX

Clinical Summary. Live Cases I - IX Clinical Summary Live Cases I - IX Patient: Male, 66 years Diagnosis: Single vessel CAD with normal LVEF Target lesion: proximal RCA Coronary risk factor: Hypertension, smoke (90py) Clinical course: ECG

More information

FFR in Multivessel Disease

FFR in Multivessel Disease FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands

More information

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe?

Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe? Euro-Asia CTO Club Can we Implement Japanese Techniques in Europe? T. Lefèvre,, Massy, France Background Despite continuous improvement, PTCA of chronic total occlusion remains a real technical challenge.

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

CLINICAL CONSEQUENCES OF THE

CLINICAL CONSEQUENCES OF THE CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL

More information

Surgery Grand Rounds

Surgery Grand Rounds Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000

More information

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers EAE Teaching Course Magnetic Resonance Imaging Competitive or Complementary? Sofia, Bulgaria, 5-7 April 2012 F.E. Rademakers Complementary? Of Course N Engl J Med 2012;366:54-63 Clinical relevance Treatment

More information

Declaration of conflict of interest NONE

Declaration of conflict of interest NONE Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages

More information

Diabetes and Occult Coronary Artery Disease

Diabetes and Occult Coronary Artery Disease Diabetes and Occult Coronary Artery Disease Mun K. Hong, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory & Interventional Cardiology St. Luke s-roosevelt Hospital Center New York, New York

More information

Fractional Flow Reserve. A physiological approach to guide complex interventions

Fractional Flow Reserve. A physiological approach to guide complex interventions Fractional Flow Reserve A physiological approach to guide complex interventions What is FFR? Fractional Flow Reserve (FFR) is a lesion specific, physiological index determining the hemodynamic severity

More information

Instantaneous Wave-Free Ratio

Instantaneous Wave-Free Ratio Instantaneous Wave-Free Ratio Alejandro Aquino MD Interventional Cardiology Fellow Washington University in St. Louis Barnes-Jewish Hospital Instantaneous Wave-Free Ratio Alejandro Aquino MD Disclosure

More information

Rational use of imaging for viability evaluation

Rational use of imaging for viability evaluation EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium

More information

ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE

ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE Angioplasty Summit TCT ASIA Seoul, Korea, april 24th, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands A rather common

More information

Fractional Flow Reserve and the Results of the FAME Study

Fractional Flow Reserve and the Results of the FAME Study Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine

More information

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia

More information

PROMUS Element Experience In AMC

PROMUS Element Experience In AMC Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical

More information

Alex versus Xience Registry Preliminary report

Alex versus Xience Registry Preliminary report Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor

More information

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular

More information

Percutaneous Coronary Interventions Without On-site Cardiac Surgery

Percutaneous Coronary Interventions Without On-site Cardiac Surgery Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future Prof. Juhani Knuuti, MD, FESC Turku, Finland Disclosure: Juhani Knuuti, M.D. Juhani Knuuti, M.D. has financial

More information

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with

More information

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES. A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.

More information

CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD. Teo et al, Canadian Journal of Cardiology 2014;30:

CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD. Teo et al, Canadian Journal of Cardiology 2014;30: CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD Teo et al, Canadian Journal of Cardiology 2014;30: 1482-1491 Parallel Paper: Canadian Cardiovascular Society Guidelines for the Diagnosis

More information

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference

More information

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.

More information

BSIC, Manchester, September 15, Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany

BSIC, Manchester, September 15, Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany BSIC, Manchester, September 15, 2006 Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany BSIC, Manchester, September 15, 2006 Chronic total occlusions update A European perspective Gerald S. Werner,

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

Approach to Multi Vessel disease with STEMI

Approach to Multi Vessel disease with STEMI Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude

More information

FFR= Qs/Qn. Ohm s law R= P/Q Q=P/R

FFR= Qs/Qn. Ohm s law R= P/Q Q=P/R 32 ο Πανελλήνιο Καρδιολογικό Συνζδριο, Θεσσαλονίκη 20/10/2011 Gould KL et al, JACC CARDIOVASC IMAG 2009 Gould KL et al AM J CARDIOL 1974 & JACC CARDIOVASC IMAG 2009 Under maximal hyperemia: Rs=Rn FFR=

More information

Assessing Myocardium at Risk: Applying SYNTAX

Assessing Myocardium at Risk: Applying SYNTAX Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program

More information

Hospital, 6 Lukon Road, Lukong Town, Changhua Shien, Taiwan 505, Taiwan.

Hospital, 6 Lukon Road, Lukong Town, Changhua Shien, Taiwan 505, Taiwan. Volume 1, Issue 1 Image Article Resolution of Inferior Wall Ischemia after Successful Revascularization of LAD Lesion: The Value of Myocardial Perfusion Imaging in Guiding Management of Multi-vessel CAD

More information

Intervention: How and to which extent is technology helping us?

Intervention: How and to which extent is technology helping us? Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction

More information

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches

More information

Retrograde Coronary Chronic Total Occlusion Revascularization

Retrograde Coronary Chronic Total Occlusion Revascularization JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 12, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.06.025

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

PCI vs. CABG From BARI to Syntax, Is The Game Over?

PCI vs. CABG From BARI to Syntax, Is The Game Over? PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease

More information

Case Presentation #1

Case Presentation #1 Case Presentation #1 SCAI Fellows Course December 7, 2013 Barry F Uretsky, MD University of Arkansas for Medical Sciences Central Arkansas Veterans Health System Little Rock, AR Case Presentation #1 65

More information

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea FFR-Guided PCI William F. Fearon, M.D. Associate Professor Division of Cardiovascular Medicine University Medical Center Disclosure Statement

More information

The SYNTAX-LE MANS Study

The SYNTAX-LE MANS Study The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS

More information

Percutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012

Percutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012 www.muthjm.com Muthanna Medical Journal 2015; 2(2):76-82 Percutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012

More information

Left Main Intervention: Will it become standard of care?

Left Main Intervention: Will it become standard of care? Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,

More information

FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT

FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT01724957 Dobrin Vassilev MD, PhD Assoc. Prof. in Cardiology Head Cardiology Clinic, Alexandrovska University Hospital Medical

More information

Better CABGs vs Better PCI Devices

Better CABGs vs Better PCI Devices CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical

More information

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users February 1 5, 2011 University of Santo Tomas Hospital Angelo King A-V Auditorium Manila,

More information

Pearls & Pitfalls in nuclear cardiology

Pearls & Pitfalls in nuclear cardiology Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer

More information

Left Main Intervention: Where are we in 2015?

Left Main Intervention: Where are we in 2015? Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa

More information

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial

More information

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,

More information

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System

Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System Volume 1, Issue 1 Case Report Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System Robert F. Riley * and Bill Lombardi University of Washington Medical Center, Division

More information

Fractional Flow Reserve and the 1 Year Results of the FAME Study

Fractional Flow Reserve and the 1 Year Results of the FAME Study Imaging and Physiology Summit Seoul, Korea, November 22, 2008 Fractional Flow Reserve and the 1 Year Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine

More information

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute

More information

FRACTIONAL FLOW RESERVE: STANDARD OF CARE

FRACTIONAL FLOW RESERVE: STANDARD OF CARE FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW

More information

Percutaneous coronary intervention of RIMA. The real challenge!

Percutaneous coronary intervention of RIMA. The real challenge! Percutaneous coronary intervention of RIMA The real challenge! Speaker's name: I do not have any potential conflict of interest Clinical Case 76-year old woman Previous History Actual Disease Diabetes

More information

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center 2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular

More information

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of

More information

@02-126_Coronary_calcification.ppt. Professor Molecular and Medical Pharmacology

@02-126_Coronary_calcification.ppt. Professor Molecular and Medical Pharmacology Assessment of Myocardial Viability Jamshid Maddahi, M.D., FACC, FASNC Professor Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (Cardiology) David Geffen School of Medicine at UCLA Director,

More information

Evaluating Clinical Risk and Guiding management with SPECT Imaging

Evaluating Clinical Risk and Guiding management with SPECT Imaging Evaluating Clinical Risk and Guiding management with SPECT Imaging Raffaele Giubbini Chair and Nuclear Medicine Unit University & Spedali Civili Brescia- Italy U.S. Congressional Budget Office. Technological

More information

Treatment Options for Angina

Treatment Options for Angina Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million

More information

Clinical case in perspective. Cases from Poland

Clinical case in perspective. Cases from Poland Clinical case in perspective Cases from Poland Assoc. Prof. Jacek Legutko, MD, PhD President-Elect of the Association for Percutaneous Cardiovascular Interventions of the Polish Cardiac Society Institute

More information

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL

More information

Fractional Flow Reserve: Review of the latest data

Fractional Flow Reserve: Review of the latest data Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most

More information

What do the guidelines say?

What do the guidelines say? Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European

More information

The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results

The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results Dr. VIVEK GUPTA MD, DM, FICC, FIC France Senior Interventional Cardiologist Indraprastha Apollo

More information

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were

More information

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio 1 STABLE ISCHEMIC HEART DISEASE: A NON-INVASIVE CARDIOLOGIST S PERSECTIVE 2018 Cardiovascular Course for Trainees and Early Career Physicians APRIL 20, 2018 David A. Orsinelli, MD, FACC, FASE Professor,

More information

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized

More information